Related Experiment Video
Updated: Jan 22, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Disease-modifying efficacy of alginate-microencapsulated probiotics in an animal model of ulcerative colitis
Mohammad Abavisani1,2, Khatereh Kharazmi3, Soheil Tafazzoli Mehrjardi4
1Antimicrobial Resistance Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
Ulcerative colitis (UC) can be challenging to control with current therapies. Modulating gut dysbiosis with probiotics is a promising approach, but the benefits depend on keeping the cell viability as they pass through gastrointestinal transit (GIT). This study developed an alginate microencapsulation system and evaluated its overall disease-modifying efficacy in an acetic acid-induced colitis model. Lactiplantibacillus plantarum and Levilactobacillus brevis were microencapsulated in calcium alginate beads via extrusion. Encapsulation efficiency, morphology, and viability under simulated GIT conditions were assessed. Forty-two male Wistar rats (non-colitic control; acetic acid-induced colitis) were gavaged for up to 12 days with normal saline, free or encapsulated probiotics, and/or mesalazine. Disease Activity Index (DAI), colon weight/length, histopathology, and colonic IFN-γ expression were measured; statistical significance was P < 0.05. Results displayed that encapsulation yielded a high efficiency (91.00% ± 1.69%). In simulated GIT conditions, Δ0-120 log CFU was significantly smaller for encapsulated than for free probiotics. Combination of encapsulated probiotics with mesalazine (EMT) showed the lowest weight loss score across all probiotic-based groups (p < 0.05). DAI declined from day 2 onward in most groups; by day 5, animals given encapsulated probiotics remained significantly different from non-colitic controls (p < 0.05). Histopathological assessment showed that either encapsulated or free probiotics significantly lower histopathological scores compared to the colitis group (p < 0.001), and real-time PCR revealed a significant difference between the EMT group compared to the colitis group (p < 0.05). Together, alginate-microencapsulated formulations were more effective than free probiotics with regard to outcome improvements, indicating a viable UC management strategy that needs further investigation.
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...

